RAS G12D Inhibitor Shows Promise in Lung Cancer

Congratulations to our friends at Revolution Medicines on their exciting updated phase 1 data. Fantastic news! These advanced therapies require well-controlled and validated supply chains from point of manufacture to point of care. We at Modality Solutions, A BlueRidge Life Sciences Company can help. Reach out if you have any questions on your #biopharma #coldchainlogistics challenges. #AACR26 #LungCancer #AdvancedTherapies #ColdChainEngineering

Phase 1/2 clinical data for our RAS(ON) multi-selective inhibitor has been published in NEJM Group.    These Phase 1/2 results contributed to the scientific and clinical rationale for RASolute 302, our pivotal Phase 3 trial in second line treatment of patients with metastatic pancreatic cancer.    Our inhibitor is also being evaluated in three other global Phase 3 registrational trials, including in patients with PDAC in earlier treatment lines and those with metastatic RAS mutant non-small cell lung cancer.     Read more: https://lnkd.in/ggXCqV3Q

According to the American Cancer Society, an estimated 333k new cases of prostate cancer will be diagnosed in the United States in 2026. Prostate cancer remains one of the most common cancers, underscoring the need for new and differentiated approaches. At Solu Therapeutics, we are advancing research through our CyTAC™ platform, exploring bispecific approaches designed to selectively target prostate cancer cells. As we recognize #NationalCancerResearchMonth, we remain focused on translating innovative science into potential new options for patients. Learn more: https://lnkd.in/efAFUfRh #NationalCancerResearchMonth

Seeing our Phase 1/2 data published in the NEJM is a proud milestone — and more importantly, a foundation we're building on at scale. These results helped shape the scientific rationale for RASolute 302 and the three additional Phase 3 trials now underway across PDAC and RAS mutant non-small cell lung cancer. From early signal to global registrational program. That's the work. #RAS(ON) #Oncology #PancreaticCancer #NSCLC #RevMed

Encouraging to see Phase 1/2 clinical data for daraxonrasib published in NEJM Group. Alongside recent FDA authorization of an expanded access program for patients with metastatic #PancreaticCancer this is an exciting moment. Through our collaboration with Revolution Medicines and The Lustgarten Foundation, Break Through Cancer is supporting a dedicated cohort within an ongoing Phase 1/2 study designed to generate deeply profiled datasets to better understand response, resistance, and next-generation strategies for RAS-targeted therapies.

Pleased to see the NEJM publication of the Phase 1/2 study evaluating daraxonrasib in metastatic PDAC. Early-phase development informing late-phase trial design, as intended. Deep gratitude to the patients, caregivers, investigators and study teams whose commitment made this work possible.

New therapies are finally arriving in Small Cell Lung Cancer—but we still can't tell early on who they're actually working for. So we asked a simpler question: what if a single tube of blood could tell us whether patients would benefit from Drug A vs B, before even starting the drug? Thank you to the Kuni Foundation for funding us with a $100,000 grant to do exactly that — Blood-Based Biomarkers to Predict Response to Novel SCLC Therapies, at the OHSU Knight Cancer Institute

After prostate and breast cancer, lung and bronchus cancer remain among the most commonly diagnosed cancers in the U.S. According to The National Institutes of Health, an estimated 299,410 new cases are expected in 2026 alone. We're honored to partner with researchers across the Pacific Northwest who are driving transformative approaches to cancer detection, treatment, and ultimately a cure. Many thanks to Dr. Rajat Thawani and the OHSU Knight Cancer Institute for advancing critical Small Cell Lung Cancer research and strengthening Oregon's bioscience ecosystem through innovation and discovery. Cancer research is a vital part of Oregon’s bioscience sector — an engine that fueled more than $11.5 billion in economic activity across the state in 2023, enhancing the vibrancy of communities throughout our region. Partnerships between philanthropy, research institutions, and industry are essential to building a healthier and more prosperous future. #SupportScience #CancerResearch #Bioscience #PacificNorthwest #Philanthropy

ctDNA is emerging as a tool for response-adapted bladder preservation in muscle-invasive bladder cancer. In the phase II RETAIN trials, ctDNA clearance was associated with improved metastasis-free survival and helped refine risk stratification in patients being considered for bladder-sparing approaches. Dr. Pooja Ghatalia, Associate Professor of Hematology and Oncology at Fox Chase Cancer Center, discussed both the prognostic value of ctDNA for systemic recurrence and its limitation in reliably detecting localized disease. She presented this work at the 2026 ASCO Genitourinary Cancers Symposium. https://lnkd.in/efNw2i2X #GlobalOncologyAcademy #oncology #precisiononcology #cancer

All what do you want to know about ADCs or Antibody drug conjugates, the hottest theraputic area for cancer treatments. Enhertu, Kadcyla, Adcetris, Polivy and Blenreb.